5-(2-methoxyethyl)pyrimidine-2,4-(1H,3H)-dione | 54127-93-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(2-methoxyethyl)pyrimidine-2,4-(1H,3H)-dione
• 英文别名: 5-(2-Methoxyethyl)-uracil；5-(2-methoxy-ethyl)-1H-pyrimidine-2,4-dione；5-(2-methoxyethyl)-1H-pyrimidine-2,4-dione
• CAS: 54127-93-4
• 化学式: C₇H₁₀N₂O₃
• 分子量: 170.168
• InChiKey: QDSSSYJCTRKILR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(2-methoxyethyl)pyrimidine-2,4-(1H,3H)-dione 在 ammonium sulfate 、 N-碘代丁二酰亚胺 、 三甲基氯硅烷 、 4 A molecular sieve 、 三氯化硼 、 六甲基二硅氮烷 作用下， 以 二氯甲烷 为溶剂， 生成 1-((2R,4S,5R)-4-Hydroxy-5-hydroxymethyl-tetrahydro-thiophen-2-yl)-5-(2-methoxy-ethyl)-1H-pyrimidine-2,4-dione
  参考文献：
  名称：

  Synthesis and Anti-Herpes Virus Activity of 2‘-Deoxy-4‘-thiopyrimidine Nucleosides

  摘要：

  A series of 5-substituted 2'-deoxy-4'-thiopyrimidine nucleosides was synthesized and evaluated as potential antiviral agents. A number of analogues such as 2'-deoxy-5-propyl-4'-thiouridine (3ii), 2'-deoxy-5-isopropyl-4'-thiouridine (3iii), 5-cyclopropyl-2'-deoxy-4'-thiouridine (3iv), 2'-deoxy-4'-thio-5-vinyluridine (3viii), and 5-(2-chloroethyl)-2'-deoxy-4'-thiouridin (3xx) were found to be highly active against herpes simplex virus type-1 (HSV-1) and varicella tester virus (VZV) in vitro with no significant cytotoxicity. The compound with the broadest spectrum of activity was 2'-deoxy-5-ethyl-4'-thiouridine (3i) which showed significant activity against HSV-1, HSV-2, and VZV.

  DOI：

  10.1021/jm950029r
• 作为产物：
  描述：

  5-(2-羟基乙基)尿嘧啶 在 吡啶 作用下， 反应 19.5h， 生成 5-(2-methoxyethyl)pyrimidine-2,4-(1H,3H)-dione
  参考文献：
  名称：

  PIPERINDIN-ONES DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF

  摘要：

  Piperidin-ones compound of formula (I), the preparation method thereof, pharmaceutcal compositions comprising the compounds, and the pharmaceutical uses for the treatment of disorders are disclosed.

  公开号：

  WO2024125451A1

文献信息

• 2-(3-Amino-2-hydroxy-propoxy)-mono-and diazines
  申请人：Ciba-Geigy Corporation

  公开号：US04410530A1

  公开（公告）日：1983-10-18

  Heterocyclic compounds of the formula ##STR1## wherein Het denotes optionally substituted pyridazinyl, pyrimidinyl, pyrazinyl or substituted pyridyl, R.sub.1 is hydrogen or methyl and R.sub.2 is lower alklyl, optionally substituted phenyl-lower alkyl, carboxy-lower alkyl or functionally modified carboxy-lower alkyl, their condensation products with aldehydes, ketones or carbonic acid and their N-oxides, which are valuable (cardioselective) .beta.-receptor blocking agents, and/or (cardioselective) .beta.-receptor-stimulants.

  式子为##STR1##的杂环化合物，其中Het表示可选取代的吡啶并嗪基、嘧啶基、吡嗪基或取代的吡啶基，R.sub.1为氢或甲基，R.sub.2为较低的烷基、可选取代的苯基-较低烷基、羧基-较低烷基或功能改性的羧基-较低烷基，它们与醛、酮或碳酸的缩合产物以及它们的N-氧化物是有价值的(心脏选择性).beta.-受体阻滞剂和/或(心脏选择性).beta.-受体刺激剂。
• 2-(3-Amino-2-hydroxy-propoxy)pyridine derivatives and pharmaceutical
  申请人：Ciba-Geigy Corporation

  公开号：US04195090A1

  公开（公告）日：1980-03-25

  Heterocyclic compounds of the formula ##STR1## wherein Het denotes optionally substituted pyridazinyl, pyrimidinyl, pyrazinyl or substituted pyridyl, R.sub.1 is hydrogen or methyl and R.sub.2 is lower alkyl, optionally substituted phenyl-lower alkyl, carboxy-lower alkyl or functionally modified carboxy-lower alkyl, their condensation products with aldehydes, ketones or carbonic acid and their N-oxides, which are valuable (cardioselective) .beta.-rezeptor blocking agents, and/or (cardioselective) .beta.-rezeptor-stimulants.

  式中，Het表示可选取代的吡啶并嗪基、嘧啶基、吡嗪基或取代的吡啶基，R.sub.1为氢或甲基，R.sub.2为低碳基、可选取代的苯基-低碳基、羧基-低碳基或功能修饰的羧基-低碳基，它们与醛、酮或碳酸的缩合产物以及它们的N-氧化物是有价值的（心脏选择性）β-受体阻滞剂和/或（心脏选择性）β-受体激动剂。
• 2-(3-Amino-2-hydroxy-propoxy)-pyrazines
  申请人：Ciba-Geigy Corporation

  公开号：US04115575A1

  公开（公告）日：1978-09-19

  Heterocyclic compounds of the formula ##STR1## wherein Het denotes optionally substituted pyridazinyl, pyrimidinyl, pyrazinyl or substituted pyridyl, R.sub.1 is hydrogen or methyl and R.sub.2 is lower alkyl, optionally substituted phenyl-lower alkyl, carboxy-lower alkyl or functionally modified carboxy-lower alkyl, their condensation products with aldehydes, ketones or carbonic acid and their N-oxides, which are valuable (cardioselective) .beta.-rezeptor blocking agents, and/or (cardioselective) .beta.-rezeptor-stimulants.

  式子为##STR1##的杂环化合物，其中Het表示可选取取代的吡嗪基、嘧啶基、吡咯基或取代的吡啶基，R.sub.1为氢或甲基，R.sub.2为低碳基、可选取取代的苯基-低碳基、羧基-低碳基或功能修饰的羧基-低碳基，它们与醛、酮或碳酸的缩合产物以及它们的N-氧化物是有价值的（心脏选择性）β受体阻滞剂和/或（心脏选择性）β受体激动剂。
• Nucleic acid aptamers to treat histone-induced disease states
  申请人：UNIVERSITY OF IOWA RESEARCH FOUNDATION

  公开号：US10633410B2

  公开（公告）日：2020-04-28

  The present invention relates to methods of using optimized aptamers. In certain embodiments, the present invention provides a method for treating a subject having or being disposed to having a histone-induced injury or disease comprising administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and (i) a nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer KU1, KU2, KU3, KU4, KU5, KU6, KU&, KU8, or KU9, wherein the aptamer specifically targets extracellular histones, wherein the nucleotides are RNA; or (ii) a conjugate comprising a nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer KU1, KU2, KU3, KU4, KU5, KU6, KU&, KU8, or KU9, wherein the aptamer specifically targets extracellular histones, wherein the nucleotides are RNA, wherein the nucleic acid molecule is linked to a therapeutic molecule.

  本发明涉及使用优化适配体的方法。在某些实施方案中，本发明提供了一种用于治疗具有组蛋白诱导的损伤或疾病的受试者或被处置为具有组蛋白诱导的损伤或疾病的受试者的方法，该方法包括向受试者施用药物组合物，该药物组合物包含药学上可接受的载体和(i)长度不超过90个核苷酸的核酸分子，该核酸分子包含适配体KU1、KU2、KU3、KU4、KU5、KU6、KU&、KU8或KU9、KU2、KU3、KU4、KU5、KU6、KU&、KU8 或 KU9，其中该适配体特异性靶向细胞外组蛋白，其中核苷酸为 RNA；或(ii)包含长度不超过 90 个核苷酸的核酸分子的共轭物，该核酸分子包含适配体 KU1、KU2、KU3、KU4、KU5、KU6、KU&、KU8 或 KU9，其中适配体特异性靶向细胞外组蛋白，其中核苷酸为 RNA，其中核酸分子与治疗分子相连。
• NUCLEIC ACID APTAMERS TO TREAT HISTONE-INDUCED DISEASE STATES
  申请人：GIANGRANDE Paloma H.

  公开号：US20180134746A1

  公开（公告）日：2018-05-17

  The present invention relates to optimized aptamers and methods of using these aptamers.